Lexaria Bioscience Corp. 8-K

What Happened Lexaria Bioscience Corp. (LEXX) filed an 8-K on Feb 6, 2026 disclosing that it received a Nasdaq Bid Price Deficiency Notice on Feb 4, 2026 saying the company is not in compliance with Nasdaq’s $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). The notice does not affect current trading — LEXX continues to trade on the Nasdaq Capital Market — but gives the company 180 calendar days, until August 3, 2026, to regain compliance by meeting the $1.00 closing bid requirement.

Key Details

• Date of notice received: February 4, 2026; 8-K filed February 6, 2026.
• Required remedy: closing bid price ≥ $1.00 per share for at least 10 consecutive business days (Nasdaq staff may extend to up to 20 consecutive business days) within the 180-day compliance period ending August 3, 2026.
• If not regained by Aug 3, 2026, Lexaria may be eligible for a second 180-day cure period only if it meets Nasdaq’s market value of publicly held shares and other initial listing standards (except the bid price); the company would need to notify Nasdaq of intent to cure, possibly by a reverse stock split.
• If the company fails both periods or does not qualify for a second period, Nasdaq could move to delist the common stock, at which point Lexaria could appeal to a Hearings Panel.

Why It Matters This notice signals a risk to Lexaria’s Nasdaq listing if the stock price remains below $1.00. Delisting could reduce liquidity, limit investor access, and negatively affect shareholder value. The company is monitoring the situation and may consider options (including a reverse split) to regain compliance, but there is no assurance it will succeed. Investors should be aware of the deadline (Aug 3, 2026) and that continued trading is currently unaffected.